Cargando…
Real‐World Clinical Effectiveness of Liraglutide 3.0 mg for Weight Management in Canada
OBJECTIVE: Real‐world clinical effectiveness of liraglutide 3.0 mg, in combination with diet and exercise, was investigated 4 and 6 months post initiation. Changes in absolute and percent body weight were examined from baseline. METHODS: A cohort of liraglutide 3.0 mg initiators in 2015 and 2016 was...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593982/ https://www.ncbi.nlm.nih.gov/pubmed/31062937 http://dx.doi.org/10.1002/oby.22462 |
_version_ | 1783430165153447936 |
---|---|
author | Wharton, Sean Liu, Aiden Pakseresht, Arash Nørtoft, Emil Haase, Christiane L. Mancini, Johanna Power, G. Sarah Vanderlelie, Sarah Christensen, Rebecca A. G. |
author_facet | Wharton, Sean Liu, Aiden Pakseresht, Arash Nørtoft, Emil Haase, Christiane L. Mancini, Johanna Power, G. Sarah Vanderlelie, Sarah Christensen, Rebecca A. G. |
author_sort | Wharton, Sean |
collection | PubMed |
description | OBJECTIVE: Real‐world clinical effectiveness of liraglutide 3.0 mg, in combination with diet and exercise, was investigated 4 and 6 months post initiation. Changes in absolute and percent body weight were examined from baseline. METHODS: A cohort of liraglutide 3.0 mg initiators in 2015 and 2016 was identified from six Canadian weight‐management clinics. Post initiation values at 4 and 6 months were compared with baseline values using a paired t test. RESULTS: The full cohort consisted of 311 participants, with 210 in the ≥ 4‐month persistence group and 167 in the ≥ 6‐month persistence group. Average baseline BMI was 40.7 kg/m(2), and weight was 114.8 kg. There was a significant change in body weight 6 and 4 months after initiation of treatment in persistent subjects (≥ 6‐month: −8.0 kg, P < 0.001; ≥ 4‐month: −7.0 kg, P < 0.001) and All Subjects, regardless of persistence (−7.3 kg; P < 0.001). Percentage change in body weight from baseline was −7.1% in the ≥ 6‐month group and −6.3% in the ≥ 4‐month group, and All Subjects lost 6.5% body weight. Of participants in the ≥ 6‐month group, 64.10% and 34.5% lost ≥ 5% and > 10% body weight, respectively. CONCLUSIONS: In a real‐world setting, liraglutide 3.0 mg, when combined with diet and exercise, was associated with clinically meaningful weight loss. |
format | Online Article Text |
id | pubmed-6593982 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-65939822019-07-10 Real‐World Clinical Effectiveness of Liraglutide 3.0 mg for Weight Management in Canada Wharton, Sean Liu, Aiden Pakseresht, Arash Nørtoft, Emil Haase, Christiane L. Mancini, Johanna Power, G. Sarah Vanderlelie, Sarah Christensen, Rebecca A. G. Obesity (Silver Spring) Original Articles OBJECTIVE: Real‐world clinical effectiveness of liraglutide 3.0 mg, in combination with diet and exercise, was investigated 4 and 6 months post initiation. Changes in absolute and percent body weight were examined from baseline. METHODS: A cohort of liraglutide 3.0 mg initiators in 2015 and 2016 was identified from six Canadian weight‐management clinics. Post initiation values at 4 and 6 months were compared with baseline values using a paired t test. RESULTS: The full cohort consisted of 311 participants, with 210 in the ≥ 4‐month persistence group and 167 in the ≥ 6‐month persistence group. Average baseline BMI was 40.7 kg/m(2), and weight was 114.8 kg. There was a significant change in body weight 6 and 4 months after initiation of treatment in persistent subjects (≥ 6‐month: −8.0 kg, P < 0.001; ≥ 4‐month: −7.0 kg, P < 0.001) and All Subjects, regardless of persistence (−7.3 kg; P < 0.001). Percentage change in body weight from baseline was −7.1% in the ≥ 6‐month group and −6.3% in the ≥ 4‐month group, and All Subjects lost 6.5% body weight. Of participants in the ≥ 6‐month group, 64.10% and 34.5% lost ≥ 5% and > 10% body weight, respectively. CONCLUSIONS: In a real‐world setting, liraglutide 3.0 mg, when combined with diet and exercise, was associated with clinically meaningful weight loss. John Wiley and Sons Inc. 2019-05-07 2019-06 /pmc/articles/PMC6593982/ /pubmed/31062937 http://dx.doi.org/10.1002/oby.22462 Text en © 2019 The Authors. Obesity published by Wiley Periodicals, Inc. on behalf of The Obesity Society (TOS) This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Articles Wharton, Sean Liu, Aiden Pakseresht, Arash Nørtoft, Emil Haase, Christiane L. Mancini, Johanna Power, G. Sarah Vanderlelie, Sarah Christensen, Rebecca A. G. Real‐World Clinical Effectiveness of Liraglutide 3.0 mg for Weight Management in Canada |
title | Real‐World Clinical Effectiveness of Liraglutide 3.0 mg for Weight Management in Canada |
title_full | Real‐World Clinical Effectiveness of Liraglutide 3.0 mg for Weight Management in Canada |
title_fullStr | Real‐World Clinical Effectiveness of Liraglutide 3.0 mg for Weight Management in Canada |
title_full_unstemmed | Real‐World Clinical Effectiveness of Liraglutide 3.0 mg for Weight Management in Canada |
title_short | Real‐World Clinical Effectiveness of Liraglutide 3.0 mg for Weight Management in Canada |
title_sort | real‐world clinical effectiveness of liraglutide 3.0 mg for weight management in canada |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593982/ https://www.ncbi.nlm.nih.gov/pubmed/31062937 http://dx.doi.org/10.1002/oby.22462 |
work_keys_str_mv | AT whartonsean realworldclinicaleffectivenessofliraglutide30mgforweightmanagementincanada AT liuaiden realworldclinicaleffectivenessofliraglutide30mgforweightmanagementincanada AT paksereshtarash realworldclinicaleffectivenessofliraglutide30mgforweightmanagementincanada AT nørtoftemil realworldclinicaleffectivenessofliraglutide30mgforweightmanagementincanada AT haasechristianel realworldclinicaleffectivenessofliraglutide30mgforweightmanagementincanada AT mancinijohanna realworldclinicaleffectivenessofliraglutide30mgforweightmanagementincanada AT powergsarah realworldclinicaleffectivenessofliraglutide30mgforweightmanagementincanada AT vanderleliesarah realworldclinicaleffectivenessofliraglutide30mgforweightmanagementincanada AT christensenrebeccaag realworldclinicaleffectivenessofliraglutide30mgforweightmanagementincanada |